Federal Circuit Holds That the PTAB Does Not Have an Impermissible Incentive to Institute IPRs
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
MOBILITY WORKX, LLC v. UNIFIED PATENTS, LLC
Before Newman, Schall, and Dyk. Appeal from the Patent Trial and Appeal Board.
Summary: Fee-funded structure of AIA review proceedings does not violate due process.
After inter partes review (“IPR”), the Board found Mobility’s patent claims invalid. Mobility appealed the decision to the Federal Circuit, arguing that the structure and funding of AIA review proceedings violates due process. Particularly, Mobility argued that the Board and the individual administrative patent judges (“APJs”) have impermissible financial incentives to institute IPRs.
The Federal Circuit rejected Mobility’s due process challenges. First, the Court distinguished the Board from the mayor’s court found impermissible in Tumey v. Ohio, 273 U.S. 510 (1927) where the mayor presiding over the proceedings received compensation if the defendant was convicted and used the fees to finance the town. The Federal Circuit explained that Congress, not the APJs, is responsible for setting the USPTO’s budget, and thus held that the fee-funded structure of IPRs does not violate due process. Second, the Federal Circuit held that individual APJs did not have an impermissible incentive to institute IPRs based on the APJ bonus structure because any interest in instituting IPRs for a bonus was too remote to violate due process.
In light of United States v. Arthrex, Inc., 141 S. Ct. 1970 (2021), the Court remanded the case to allow the Patent Office Director to review the Board’s final written decision and did not reach the merits of the patentability issue.
Judge Newman concurred with the decision to remand but dissented from the rest of the opinion. In her dissent, Judge Newman addressed multiple constitutional concerns raised by Mobility, including a possible Appointments Clause violation by delegating the institution decision to the Board and bias in having the same Board decide institution and patentability.
Editor: Paul Stewart
Written by: Suyoung Jang & Kendall Loebbaka
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…